The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.
Noninvasive method could help monitor treatment responses.
Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.
Phase 3 clinical trial of combination shows survival and quality-of-life benefits vs the standard of care, sorafenib, leading to the regimen’s expedited regulatory approval.
Binimetinib plus imatinib in the frontline setting appeared to improve outcomes for patients with advanced gastrointestinal stromal tumor, warranting further study.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Although some tumors lack aneuploidy or have few extra chromosomal copies, others have a slew of mutations.
All patients enrolled in the phase 3 study had metastatic CRC characterized as MSI-H/dMMR, a biomarker found in only approximately 5% of these tumors.
T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.
Trememlimumab thought to induce immune response.
Antibody-drug conjugate trastuzumab deruxtecan demonstrated promising efficacy against relapsed, metastatic, HER2+ CRC according to results from a phase 2 trial.
A phase 2/3 trial found that patients with advanced HCC who received donafenib had significantly longer OS compared with sorafenib, the standard first-line therapy.
Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.
These study findings show that weight loss occurred early among patients with advanced gastric cancer and was associated with shorter overall survival.